GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.
GLP-1
Heart Failure with Preserved Ejection Fraction
Inflammation
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
accepted:
02
10
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
19
10
2024
Statut:
aheadofprint
Résumé
Heart Failure with Preserved Ejection Fraction (HFpEF) represents a significant challenge in modern cardiovascular medicine, characterized by diastolic dysfunction and a chronic pro-inflammatory milieu. The high prevalence of comorbidities such as diabetes, visceral obesity, and aging, which contribute to systemic inflammation, plays a pivotal role in the pathogenesis and progression of HFpEF. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), a class of glucose-lowering drugs, have demonstrated a wide range of pleiotropic effects that extend beyond glycaemic control. These effects include the reduction of inflammation and oxidative stress, vasodilation, decreased arterial stiffness, and a reduction in myocardial fibrosis-key factors in the pathophysiology of HFpEF. Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF. These trials also demonstrated a significant reduction in C-Reactive Protein (CRP) levels, reinforcing the hypothesis that suppressing the pro-inflammatory state may yield substantial clinical benefits in this patient population. These findings suggest that GLP-1 RAs could play a crucial role in the management of HFpEF, particularly in patients with obesity, by targeting the underlying inflammatory processes and contributing to better overall cardiovascular outcomes.
Identifiants
pubmed: 39425816
doi: 10.1007/s10741-024-10450-6
pii: 10.1007/s10741-024-10450-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation. 109(21 Suppl 1):II2-10. https://doi.org/10.1161/01.CIR.0000129535.04194.38
doi: 10.1161/01.CIR.0000129535.04194.38
pubmed: 15173056
Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695
doi: 10.1056/NEJMra043430
pubmed: 15843671
Ridker PM (2016) From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 118(1):145–156. https://doi.org/10.1161/CIRCRESAHA.115.306656
doi: 10.1161/CIRCRESAHA.115.306656
pubmed: 26837745
pmcid: 4793711
Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE (2023) Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. The Lancet 401(10384):1293–1301. https://doi.org/10.1016/S0140-6736(23)00215-5
doi: 10.1016/S0140-6736(23)00215-5
Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 107(3):499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45
doi: 10.1161/01.CIR.0000052939.59093.45
pubmed: 12551878
Nicklas BJ, You T, Pahor M (2005) Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ Canadian Med Assoc J 172(9):1199–1209. https://doi.org/10.1503/cmaj.1040769
doi: 10.1503/cmaj.1040769
Simmonds SJ, Cuijpers I, Heymans S, Jones EAV (2020) Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells 9(1):242. https://doi.org/10.3390/cells9010242
doi: 10.3390/cells9010242
pubmed: 31963679
pmcid: 7016826
Schiattarella GG, Rodolico D, Hill JA (2021) Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res 117(2):423–434. https://doi.org/10.1093/cvr/cvaa217
doi: 10.1093/cvr/cvaa217
pubmed: 32666082
Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271. https://doi.org/10.1016/j.jacc.2013.02.092
doi: 10.1016/j.jacc.2013.02.092
pubmed: 23684677
Nair N (2020) Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med 21(4):531–540. https://doi.org/10.31083/J.RCM.2020.04.154
doi: 10.31083/J.RCM.2020.04.154
pubmed: 33387998
DuBrock HM, AbouEzzeddine OF, Redfield MM (2018) High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PLoS ONE 13(8):1–16. https://doi.org/10.1371/journal.pone.0201836
doi: 10.1371/journal.pone.0201836
Sanders-Van Wijk S, Van Empel V, Davarzani N et al (2015) Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 17(10):1006–1014. https://doi.org/10.1002/ejhf.414
doi: 10.1002/ejhf.414
pubmed: 26472682
D’Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M (2015) Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail 17(12):1231–1239. https://doi.org/10.1002/ejhf.430
doi: 10.1002/ejhf.430
pubmed: 26493383
Westermann D, Lindner D, Kasner M et al (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4(1):44–52. https://doi.org/10.1161/CIRCHEARTFAILURE.109.931451
doi: 10.1161/CIRCHEARTFAILURE.109.931451
pubmed: 21075869
Tardif JC, Kouz S, Waters David D, Bertrand OF et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497–2505. https://doi.org/10.1056/NEJMoa1912388
doi: 10.1056/NEJMoa1912388
pubmed: 31733140
Nidorf SM, Fiolet ATL, Mosterd A et al (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383:1838–1847. https://doi.org/10.1056/NEJMoa2021372
doi: 10.1056/NEJMoa2021372
pubmed: 32865380
Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131. https://doi.org/10.1056/nejmoa1707914
doi: 10.1056/nejmoa1707914
pubmed: 28845751
Mann DL, McMurray JJV, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109(13):1594–1602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2
doi: 10.1161/01.CIR.0000124490.27666.B2
pubmed: 15023878
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH. Circulation 107(25):3133–3140. https://doi.org/10.1161/01.CIR.0000077913.60364.D2
doi: 10.1161/01.CIR.0000077913.60364.D2
pubmed: 12796126
Ridker PM (2021) From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res 117(11):e138–e140. https://doi.org/10.1093/cvr/cvab231
Ridker PM, Devalaraja M, Baeres FMM et al (2021) IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397(10289):2060–2069. https://doi.org/10.1016/S0140-6736(21)00520-1
doi: 10.1016/S0140-6736(21)00520-1
pubmed: 34015342
Petrie M, Borlaug B, Buchholtz K et al (2024) HERMES: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. J Card Fail 30(1):126. https://doi.org/10.1016/j.cardfail.2023.10.024
doi: 10.1016/j.cardfail.2023.10.024
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247–2257. https://doi.org/10.1056/nejmoa1509225
doi: 10.1056/nejmoa1509225
pubmed: 26630143
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322. https://doi.org/10.1056/nejmoa1603827
doi: 10.1056/nejmoa1603827
pubmed: 27295427
pmcid: 4985288
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844. https://doi.org/10.1056/nejmoa1607141
doi: 10.1056/nejmoa1607141
pubmed: 27633186
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239. https://doi.org/10.1056/nejmoa1612917
doi: 10.1056/nejmoa1612917
pubmed: 28910237
pmcid: 9792409
Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519–1529. https://doi.org/10.1016/S0140-6736(18)32261-X
doi: 10.1016/S0140-6736(18)32261-X
pubmed: 30291013
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
doi: 10.1016/S0140-6736(19)31149-3
pubmed: 31189511
Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385(10):896–907. https://doi.org/10.1056/nejmoa2108269
doi: 10.1056/nejmoa2108269
pubmed: 34215025
Husain M, Birkenfeld AL, Donskmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 841–851. https://doi.org/10.1056/NEJMoa1901118
Marx N, Federici M, Schütt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043–4140. https://doi.org/10.1093/eurheartj/ehad192
doi: 10.1093/eurheartj/ehad192
pubmed: 37622663
Dietrich M, Jialal I (2005) The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev 63(1):22–28. https://doi.org/10.1301/nr.2004.janr.22-28
doi: 10.1301/nr.2004.janr.22-28
pubmed: 15730232
Kitzman DW, Brubaker P, Morgan T et al (2016) Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA - J Am Med Assoc 315(1):36–46. https://doi.org/10.1001/jama.2015.17346
doi: 10.1001/jama.2015.17346
Kitzman DW, Lam CSP (2017) Obese heart failure with preserved ejection fraction phenotype: from pariah to central player. Circulation 136(1):20–23. https://doi.org/10.1161/CIRCULATIONAHA.117.028365
doi: 10.1161/CIRCULATIONAHA.117.028365
pubmed: 28674090
Pugliese NR, Paneni F, Mazzola M et al (2021) Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail 23(11):1858–1871. https://doi.org/10.1002/ejhf.2337
doi: 10.1002/ejhf.2337
pubmed: 34427016
Pouliopoulos J, Chik WWB, Kanthan A et al (2013) Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation 128(21):2296–2308. https://doi.org/10.1161/CIRCULATIONAHA.113.002238
doi: 10.1161/CIRCULATIONAHA.113.002238
pubmed: 24036606
Kahles F, Meyer C, Möllmann J et al (2014) GLP-1 Secretion is increased by inflammatory stimuli in an IL-6 – dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63(April):3221–3229. https://doi.org/10.2337/db14-0100
doi: 10.2337/db14-0100
pubmed: 24947356
Lebherz C, Kahles F, Piotrowski K et al (2016) Interleukin - 6 predicts inflammation - induced increase of glucagon - like peptide - 1 in humans in response to cardiac surgery with association to parameters of glucose metabolism. Cardiovasc Diabetol 3:15–21. https://doi.org/10.1186/s12933-016-0330-8
doi: 10.1186/s12933-016-0330-8
Ellingsgaard H, Hauselmann I, Schuler B et al (2015) Interleukin-6 enhances insulin secretion by increasing glucagon- like peptide-1 secretion from L cells and alpha cells. Nat Med 17(11):1481–1489. https://doi.org/10.1038/nm.2513.Interleukin-6
doi: 10.1038/nm.2513.Interleukin-6
Nguyen AT, Mandard S, Dray C et al (2013) Lipopolysaccharides-Mediated increase in glucose-stimulated insulin secretion : involvement of the GLP-1 pathway. Diabetes 2014(63):471–482. https://doi.org/10.2337/db13-0903
doi: 10.2337/db13-0903
Bendotti G, Montefusco L, Lunati ME et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res 182(June):106320. https://doi.org/10.1016/j.phrs.2022.106320
doi: 10.1016/j.phrs.2022.106320
pubmed: 35738455
Dushay J, Chui PC, Gopalakrishnan GS et al (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139(2):456–463. https://doi.org/10.1053/j.gastro.2010.04.054
doi: 10.1053/j.gastro.2010.04.054
pubmed: 20451522
Lee YS, Park MS, Choung JS et al (2012) Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55(9):2456–2468. https://doi.org/10.1007/s00125-012-2592-3
doi: 10.1007/s00125-012-2592-3
pubmed: 22722451
Puglisi S, Rossini A, Poli R et al (2021) Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol (Lausanne) 12(October):1–10. https://doi.org/10.3389/fendo.2021.738848
doi: 10.3389/fendo.2021.738848
Yu JH, Park SY, Lee DY, Kim NH, Seo JA (2022) GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Res Clin Pract 41(2):136–149. https://doi.org/10.23876/j.krcp.22.001
doi: 10.23876/j.krcp.22.001
pubmed: 35391537
pmcid: 8995488
Ussher JR, Drucker DJ (2014) Cardiovascular actions of incretin-based therapies. Circ Res 114:1788–1803. https://doi.org/10.1161/CIRCRESAHA.114.301958
doi: 10.1161/CIRCRESAHA.114.301958
pubmed: 24855202
Arakawa M, Mita T, Azuma K et al (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like. Diabetes 59(April). https://doi.org/10.2337/db09-1694
Nagashima M, Watanabe T, Terasaki M (2011) Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54:2649–2659. https://doi.org/10.1007/s00125-011-2241-2
doi: 10.1007/s00125-011-2241-2
pubmed: 21786155
pmcid: 3168747
Bray JJH, Foster-Davies H, Salem A et al (2021) Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab 23(8):1806–1822. https://doi.org/10.1111/dom.14399
doi: 10.1111/dom.14399
pubmed: 33830637
Iacobellis G, Villasante Fricke AC (2020) Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc 4(4):1–9. https://doi.org/10.1210/JENDSO/BVZ042
doi: 10.1210/JENDSO/BVZ042
Margulies KB, Hernandez AF, Redfield MM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA - J Am Med Assoc 316(5):500–508. https://doi.org/10.1001/jama.2016.10260
doi: 10.1001/jama.2016.10260
Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69–77. https://doi.org/10.1002/ejhf.657
doi: 10.1002/ejhf.657
pubmed: 27790809
Kosiborod MN, Abildstrøm SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389(12):1069–1084. https://doi.org/10.1056/nejmoa2306963
doi: 10.1056/nejmoa2306963
pubmed: 37622681
Kosiborod MN, Petrie MC, Borlaug BA et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 390(15):1394–1407. https://doi.org/10.1056/nejmoa2313917
doi: 10.1056/nejmoa2313917
pubmed: 38587233
Butler J, Shah SJ, Petrie MC et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 403(10437):1635–1648. https://doi.org/10.1016/S0140-6736(24)00469-0
doi: 10.1016/S0140-6736(24)00469-0
pubmed: 38599221
pmcid: 11317105
Lakhani I, Wong MV, Hung JKF et al (2021) Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev 26:1141–1150. https://doi.org/10.1007/s10741-020-09927-x
doi: 10.1007/s10741-020-09927-x
pubmed: 32030562
Fragasso G (2023) The concept of “heart failure with preserved ejection fraction”: time for a critical reappraisal. Rev Cardiovasc Med 24(7):202. https://doi.org/10.31083/j.rcm2407202
doi: 10.31083/j.rcm2407202
pubmed: 39076999
pmcid: 11266467